ArticleLeukemia2017
NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group.
Abstract read
In one paragraph
Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Improved outcomes of the refined risk-stratification and risk-adapted therapy in children with acute myeloid leukemia: final results of the AIEOP AML 2013.Journal of hematology & oncology · 2026Trial
- A New Paradigm for Pediatric AML: Improving the Pipeline for Treatments Targeting Cytogenetic and Molecular Alterations.Cancers · 2026Review
- Menin inhibitors as a treatment for acute leukemia: from bench to the clinic.Blood neoplasia · 2026Review
- [Prognostic analysis of NUP98 rearrangement in patients with pediatric acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Advancing precision therapy in pediatric acute myeloid leukemia through PDX models and mitochondrial targeting.Blood advances · 2026Article
- RareAmerican journal of cancer research · 2026Article
- Using genomics to refine pediatric AML risk stratification.Hematology. American Society of Hematology. Education Program · 2025Review
- Promising activity of Selinexor in the treatment of a patient with refractory NUP98-NSD1+/FLT3-ITD + acute myeloid leukemia.Annals of hematology · 2025Article
- HoxBlinc lncRNA reprograms CTCF-independent TADs to drive leukemic transcription and HSC dysregulation in NUP98-rearranged leukemia.The Journal of clinical investigation · 2025Article
- NUP98 is rearranged in 5.0% of adult East Asian patients with AML.Blood advances · 2024Article
- NUP98 oncofusions in myeloid malignancies: An update on molecular mechanisms and therapeutic opportunities.HemaSphere · 2024Review
- Clinical features and prognosis of patients with myeloid neoplasms harboring t(7;11)(p15;p15) translocation: a single-center retrospective study.BMC cancer · 2024Article
- Combination of menin and kinase inhibitors as an effective treatment for leukemia with NUP98 translocations.Leukemia · 2024Article
- Phase separation is regulated by post-translational modifications and participates in the developments of human diseases.Heliyon · 2024Review
- Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression.European journal of medical genetics · 2023Review
- Article
- Article
- Abnormal phase separation of biomacromolecules in human diseases.Acta biochimica et biophysica Sinica · 2023Review
- The pediatric leukemia oncoprotein NUP98-KDM5A induces genomic instability that may facilitate malignant transformation.Cell death & disease · 2023Article
- Extranodal Biphenotypic Non-Hodgkin Lymphoma of the Popliteal Cavity: A Case Report and Review of Literature.Diagnostics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
V BisioDipartimento di Salute della Donna e del Bambino, Clinica di Oncoematologia Pediatrica, Università di Padova, Padova, Italy.
M ZampiniIstituto di Ricerca Pediatrica-Città della Speranza, Padova, Italy.
C TregnagoDipartimento di Salute della Donna e del Bambino, Clinica di Oncoematologia Pediatrica, Università di Padova, Padova, Italy.
E ManaraIstituto di Ricerca Pediatrica-Città della Speranza, Padova, Italy.
V SalsiDipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, University of Modena and Reggio Emilia, Modena, Italy.
A Di MeglioIstituto di Ricerca Pediatrica-Città della Speranza, Padova, Italy.
R MasettiClinica Pediatrica, Università di Bologna, Ospedale 'S. Orsola', Bologna, Italy.
M TogniClinica Pediatrica, Università di Bologna, Ospedale 'S. Orsola', Bologna, Italy.
D Di GiacomoDepartment of Medicine, Laboratory of Molecular Medicine, CREO, University of Perugia, Perugia, Italy.
S MinuzzoDipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche, Università di Padova, Padova, Italy.
A LeszlUOC Oncoematologia Pediatrica, Azienda Ospedaliera-Università degli Studi di Padova, Padova, Italy.
V ZappavignaDepartment of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.
R RondelliClinica Pediatrica, Università di Bologna, Ospedale 'S. Orsola', Bologna, Italy.
C MecucciDepartment of Medicine, Laboratory of Molecular Medicine, CREO, University of Perugia, Perugia, Italy.
A PessionClinica Pediatrica, Università di Bologna, Ospedale 'S. Orsola', Bologna, Italy.
F LocatelliDepartment of Pediatric Hematology/Oncology, IRCCS Bambino Gesù Children's Hospital, Rome, Università di Pavia, Italy.
G BassoDipartimento di Salute della Donna e del Bambino, Clinica di Oncoematologia Pediatrica, Università di Padova, Padova, Italy.
M PigazziDipartimento di Salute della Donna e del Bambino, Clinica di Oncoematologia Pediatrica, Università di Padova, Padova, Italy.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsAsparaginaseBiomarkers, TumorCyclophosphamideCytarabineDaunorubicinDown-RegulationHumansLeukemia, Myeloid, AcuteMercaptopurineMethotrexateMutationNuclear Pore Complex ProteinsOncogene Proteins, FusionPrednisonePrognosisAsparaginaseBiomarkers, TumorCyclophosphamideCytarabineDaunorubicinMercaptopurineMethotrexateNuclear Pore Complex ProteinsNup98 protein, humanOncogene Proteins, FusionPrednisoneVincristine
Identifiers
PMID
27890935What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.